Mehta R, Almeda-Valdés P, Juárez-Comboni SC, Yamamoto-Cuevas J

Language: Spanish
References: 0
Page: 301-309
PDF size: 381.97 Kb.

ABSTRACT

Type 2 diabetes mellitus is a disease with a complex pathophysiology, in which glucose often remains elevated despite the use of currently available glucose lowering drugs. The inhibitors of the type 2 sodium glucose cotransporter (iSGLT₂) constitute the first pharmacologic group of antihyperglycemic agents that target the kidneys; the objective betransporing the elimination of excess glucose in urine. In comparison with the traditional oral anti-diabetic drugs, the iSGLT₂ offer a mechanism of action independent of the β cells and insulin, inhibiting renal glucose reabsorption and promoting its urinary excretion. In this article the role of empagliflozin in the treatment of adults with type 2 diabetes mellitus is reviewed. In the preclinical analyses, empagliflozin has demonstrated a potent and selective inhibition of the SGLT₂. The phase II and III studies confirm adequate efficacy in regulating glucose homeostasis without an increased risk of hypoglycemia, accompanied with significant weight reduction and a blood pressure lowering effect. No significant drug interactions have been noted with this medication. In conjunction, the afore mentioned characteristics make empagliflozin an attractive antidiabetic drugs for the treatment of adults with type 2 diabetes mellitus that do not respond adequately to conventional agents.